Evidence map›Paper›PMID 37368233›Full record

ArticleEndocrine2023

Effect of a single dose of zoledronic acid on bone mineral density and trabecular bone score in Indian postmenopausal osteoporotic women with and without type 2 diabetes mellitus - A prospective cohort pilot study.

Chandhana Merugu, Jayaprakash Sahoo, Sadishkumar Kamalanathan, Govindarajalou Ramkumar, Sagili Vijaya Bhaskar Reddy, Sitanshu Sekhar Kar, Dukhabandhu Naik, Ayan Roy, Niya Narayanan, Deepika Patel and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Chandhana MeruguDepartment of Endocrinology, JIPMER, Puducherry, India.
Jayaprakash SahooDepartment of Endocrinology, JIPMER, Puducherry, India. jppgi@yahoo.com.ORCID 0000-0002-8805-143X
Sadishkumar KamalanathanDepartment of Endocrinology, JIPMER, Puducherry, India.
Govindarajalou RamkumarDepartment of Radiodiagnosis, JIPMER, Puducherry, India.
Sagili Vijaya Bhaskar ReddyVijay Diabetes, Thyroid and Endocrine Clinic, Puducherry, India.
Sitanshu Sekhar KarDepartment of Preventive and Social Medicine, JIPMER, Puducherry, India.
Dukhabandhu NaikDepartment of Endocrinology, JIPMER, Puducherry, India.
Ayan RoyDepartment of Endocrinology, AIIMS, Kalyani, West Bengal, India.
Niya NarayananDepartment of Endocrinology, JIPMER, Puducherry, India.
Deepika PatelDepartment of Endocrinology, JIPMER, Puducherry, India.
Varun SuryadevaraDepartment of Endocrinology, JIPMER, Puducherry, India.
Jawaharlal Institute of Post Graduate Medical Education and Research · INAll India Institute of Medical Sciences Raipur · IN

Funding

Jawaharlal Institute Of Postgraduate Medical Education and Research JIP/Res/Intramural/Phs 2 /2018-2019The Endocrine Society of India TG2019015/18-10-2019
6 · The paper itself

Abstract

purposeThe objectives were to study the effect of a single dose of intravenous (IV) zoledronic acid (ZA) on changes in bone mineral density (BMD) (lumbar spine (LS), hip, & distal forearm), trabecular bone score (TBS) and bone turnover markers (BTMs) in postmenopausal osteoporotic women with and without diabetes over 12 months.

methodsPatients were divided into two groups: type 2 diabetes mellitus (T2DM) (n = 40) and non-DM (n = 40). Both groups received a single dose of 4 mg IV ZA at baseline. The BMD with TBS and BTMs (β-CTX, sclerostin, P1NP) were measured at baseline, six months, and 12 months.

resultsAt baseline, BMD in all three sites was similar in both groups. T2DM patients were older and had lower BTMs than non-DM patients. The mean increase in LS-BMD (gram/cm

conclusionThe gain in the LS-BMD was significantly lower in T2DM group compared to non-DM subjects over 12 months after a single IV infusion of 4 mg ZA. The explanation for this could be low bone turnover in diabetes subjects at baseline.

Indexed as

Diabetes Mellitus, Type 2Osteoporotic FracturesAbsorptiometry, PhotonBone DensityCancellous BoneFemaleHumansLumbar VertebraePilot ProjectsPostmenopauseProspective StudiesZoledronic AcidZoledronic AcidBisphosphonatesBone mineral densityBone turnover markersFractureTrabecular bone score

Identifiers

PMID37368233
OpenAlexW4382181309

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.